Towards Clinically Actionable Machine Learning and Artificial Intelligence Algorithms in Acute Leukemia: A Systematic Narrative Review [0.03%]
急性白血病临床行动指南之机器学习和人工智能算法的系统叙述性综述
Jean Mg Sabile,Ping Zhang,Anil V Parwani et al.
Jean Mg Sabile et al.
Introduction: Acute myeloid leukemia (AML) is a heterogenous hematologic malignancy that maintains high relapse rates and poor survival despite ongoing treatment advances. There is critically unmet need for consistently p...
Shekhar Krishnan,Vaskar Saha
Shekhar Krishnan
Background Acute lymphoblastic leukaemia (ALL) is the commonest paediatric cancer and represents a fifth of adult leukaemias. Global outcome disparities are linked to variations in sociodemographic indices (SDI). Summary In high-SDI regions...
Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists [0.03%]
BTK抑制剂治疗慢性淋巴细胞白血病患者心血管不良反应的管理共识：血液科和心内科专家共识报告
Talha Munir,Eglė Čiburienė,Vasko Graklanov et al.
Talha Munir et al.
Background: Cardiovascular (CV) adverse events (AEs), especially atrial fibrillation (AF) and hypertension, have been reported in patients receiving treatments for chronic lymphocytic leukemia (CLL), including Bruton's ty...
Vera Sorin,Israel Cohen,Ruth Lekach et al.
Vera Sorin et al.
Lymphomas are a diverse group of disorders characterized by the clonal proliferation of lymphocytes. While definitive diagnosis of lymphoma relies on histopathology, immune-phenotyping and additional molecular analyses, imaging modalities s...
Complexities of MRD Assays in ALL: A Guide for the Practicing Clinician [0.03%]
急性淋巴细胞白血病MRD检测的复杂性：临床医师指导手册
Jerry Luo,Lori Muffly
Jerry Luo
Assessment of measurable residual disease (MRD) is an important component of acute lymphoblastic leukemia (ALL) management. Quantification of MRD may be performed through a variety of assays, each with differing sensitivity for leukemia det...
Impact of Early-Onset or Worsening Anemia in Patients With Myelofibrosis Treated With Ruxolitinib: A Post Hoc Analysis of the JUMP Study [0.03%]
JUMP研究的回顾性分析：芦可替尼治疗患者的早期发生或加重贫血的影响
Haifa Kathrin Al-Ali,Paola Guglielmelli,Claire N Harrison et al.
Haifa Kathrin Al-Ali et al.
Introduction: Anemia can influence decisions regarding initiation, dosing, and discontinuation of Janus kinase inhibitor therapy for myelofibrosis. We evaluated the impact of new-onset or worsening anemia following ruxoli...
Venetoclax-based regimen in refractory or relapsed pediatric acute lymphoblastic leukemia [0.03%]
用于儿童难治性和复发性急性淋巴细胞白血病的 venetoclax 方案
Lin Zhang,Zhixiao Zhang,Aidong Lu et al.
Lin Zhang et al.
Introduction: This study investigated the efficacy and survival of pediatric refractory or relapsed (R/R) acute lymphoblastic leukemia (ALL) treated with a venetoclax (VEN)-based regimen. ...
Identification and Confirmation of Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review [0.03%]
美国真实世界中带有FGFR1重排的髓系/淋巴组织肿瘤的识别与确认及治疗模式和结局特征的病历回顾研究
Shreekant Parasuraman,Kimberly Saverno,Kristin Zimmerman Savill et al.
Shreekant Parasuraman et al.
Introduction: Myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1) are rare, heterogenous, aggressive hematologic malignancies with FGFR1 rearrangements at the 8p11 locus. Pemigati...
Exploration of B and T cell receptor repertoires reveals distinct mechanisms in pure red cell aplasia, autoimmune hemolytic anemia, and aplastic anemia [0.03%]
探究B细胞受体和T细胞受体的互补决定区 repertoire 在纯红细胞再生障碍、自身免疫性溶血性贫血以及再生障碍性贫血中的不同机制
Ruoxi Zhang,Bing Han
Ruoxi Zhang
Background: Pure red cell aplasia (PRCA), autoimmune hemolytic anemia (AIHA) and aplastic anemia (AA) are immune-mediated diseases that affect mainly erythrocytes or erythroid progenitor cells. This study aimed to investi...
Anna Østergaard,Ilaria Iacobucci
Anna Østergaard
Over the last two decades, significant improvements have been made in the understanding of the genomic and biological bases of acute lymphoblastic leukemia (ALL), resulting in enhanced genomic classification, more precise risk stratificatio...